Literature DB >> 17445589

Effect of bisphosphonates on bone mineral density after renal transplantation as assessed by bone mineral densitometry.

B Nayak1, S Guleria, M Varma, N Tandon, S Aggarwal, D Bhowmick, S K Agarwal, S Mahajan, S Gupta, S C Tiwari.   

Abstract

INTRODUCTION: Steroid-induced osteoporosis is a major problem after organ transplantation. There is considerable evidence that bisphosphonates are effective in decreasing osteoporosis. AIM: This prospective study was carried out to see the effects of bisphosphonates on bone mineral density (BMD) after successful renal transplantation.
MATERIAL AND METHODS: Fifty consecutive patients of successful renal transplantation were randomized into two groups. Group A (n = 27) received 35 mg/wk of Alendronate for 6 months after transplantation. Group B (n = 23) did not receive Alendronate and served as a control. Both groups underwent a pretransplant baseline dual-energy X-ray absorptiometry (DEXA) scan of their hips and lumber spines. Both groups received oral calcium and vitamin D supplement. Both groups were matched for the regimen and dose of immunosuppressive drugs. BMD was measured at 3 months and 6 months after transplantation.
RESULTS: Both groups showed a decline in BMD in early months posttransplantation. However, the 6-month DEXA scans showed a significant rise in BMD in group A as compared to group B.
CONCLUSION: Bisphosphonates appear to have a beneficial effect on steroid-induced bone loss.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17445589     DOI: 10.1016/j.transproceed.2007.01.065

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  7 in total

1.  Individualized therapy to prevent bone mineral density loss after kidney and kidney-pancreas transplantation.

Authors:  Rahul Mainra; Grahame J Elder
Journal:  Clin J Am Soc Nephrol       Date:  2009-12-03       Impact factor: 8.237

2.  Effect of risedronate on bone in renal transplant recipients.

Authors:  Maria Coco; James Pullman; Hillel W Cohen; Sally Lee; Craig Shapiro; Clemencia Solorzano; Stuart Greenstein; Daniel Glicklich
Journal:  J Am Soc Nephrol       Date:  2012-07-12       Impact factor: 10.121

Review 3.  Interventions for preventing bone disease in kidney transplant recipients.

Authors:  Suetonia C Palmer; Edmund Ym Chung; David O McGregor; Friederike Bachmann; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2019-10-22

4.  Efficacy and Safety of Different Bisphosphonates for Bone Loss Prevention in Kidney Transplant Recipients: A Network Meta-Analysis of Randomized Controlled Trials.

Authors:  Yan Yang; Shi Qiu; Xi Tang; Xin-Rui Li; Ling-Hui Deng; Qiang Wei; Ping Fu
Journal:  Chin Med J (Engl)       Date:  2018-04-05       Impact factor: 2.628

5.  Use of alendronate sodium (Fosamax) to ameliorate osteoporosis in renal transplant patients: a case-control study.

Authors:  Wen-Hung Huang; Shen-Yang Lee; Cheng-Hao Weng; Ping-Chin Lai
Journal:  PLoS One       Date:  2012-11-20       Impact factor: 3.240

Review 6.  Efficacy and Safety of Bisphosphonates for Low Bone Mineral Density After Kidney Transplantation: A Meta-Analysis.

Authors:  Shun-Li Kan; Guang-Zhi Ning; Ling-Xiao Chen; Yong Zhou; Jing-Cheng Sun; Shi-Qing Feng
Journal:  Medicine (Baltimore)       Date:  2016-02       Impact factor: 1.889

7.  Outcomes of bisphosphonate and its supplements for bone loss in kidney transplant recipients: a systematic review and network meta-analysis.

Authors:  Yan Yang; Shi Qiu; Linghui Deng; Xi Tang; Xinrui Li; Qiang Wei; Ping Fu
Journal:  BMC Nephrol       Date:  2018-10-19       Impact factor: 2.388

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.